In vitro activities of the β-lactamase inhibitors clavulanic acid, sulbactam, and tazobactam alone or in combination with β-lactams against epidemiologically characterized multidrug-resistant Acinetobacter baumannii strains

被引:96
作者
Higgins, PG [1 ]
Wisplinghoff, H [1 ]
Stefanik, D [1 ]
Seifert, H [1 ]
机构
[1] Univ Cologne, Inst Med Microbiol Immunol & Hyg, D-50935 Cologne, Germany
关键词
D O I
10.1128/AAC.48.5.1586-1592.2004
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
Acinetobacter baumannii is an important nosocomial pathogen usually in the context of serious underlying disease. Multidrug resistance in these organisms is frequent. The beta-lactamase inhibitors clavulanic acid, sulbactam, and tazobactam have intrinsic activity against Acinetobacter strains. To evaluate their potential therapeutic usefulness, we determined the in vitro activity of ampicillin, sulbactam, ampicillin-sulbactam, cefoperazone, cefoperazone-sulbactam, piperacillin, piperacillin-sulbactam, tazobactam, piperacillin-tazobactam, amoxicillin, clavulanic acid, amoxicillin-clavulanic acid, ticarcillin, and ticarcillin-clavulanic acid against multidrug-resistant A. baumannii. All isolates were epidemiologically characterized by RAPD [random(ly) amplified polymorphic DNA] analysis and/or pulsed-field gel electrophoresis and represented different strain types, including sporadic strains, as well as outbreak-related strains. The MICs were determined by agar dilution on Mueller-Hinton agar (using fixed concentrations, as well as fixed ratios for beta-lactamase inhibitors) and the E-test. The majority of E-test results were within two dilutions of those recorded by agar dilution, with the exception of piperacillin-tazobactam. Sulbactam was superior to clavulanic acid and tazobactam and may represent an alternative treatment option for infections due to multiresistant A. baumannii strains. beta-Lactamase inhibitors have intrinsic activity but do not enhance activity of beta-lactams against A. baumannii. Testing with the inhibitor added at a fixed concentration as recommended for piperacillin-tazobactam and ticarcillin-clavulanic acid by the National Committee for Clinical Laboratory Standards may falsely suggest high activity or gives uninterpretable results due to trailing. If combinations are used for testing, fixed ratios may give more useful results.
引用
收藏
页码:1586 / 1592
页数:7
相关论文
共 33 条
[11]   Comparative activities of ciprofloxacin, clinafloxacin, gatifloxacin, gemifloxacin, levofloxacin, moxifloxacin, and trovafloxacin against epidemiologically defined Acinetobacter baumannii strains [J].
Heinemann, B ;
Wisplinghoff, H ;
Edmond, M ;
Seifert, H .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2000, 44 (08) :2211-2213
[12]   Antibiotic resistance among clinical isolates of Acinetobacter in the UK, and in vitro evaluation of tigecycline (GAR-936) [J].
Henwood, CJ ;
Gatward, T ;
Warner, M ;
James, D ;
Stockdale, MW ;
Spence, RP ;
Towner, KJ ;
Livermore, DM ;
Woodford, N .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2002, 49 (03) :479-487
[13]   Treatment of multidrug-resistant Acinetobacter baumannii meningitis with ampicillin/sulbactam [J].
JimenezMejias, ME ;
Pachon, J ;
Becerril, B ;
PalominoNicas, J ;
RodriguezCobacho, A ;
Revuelta, M .
CLINICAL INFECTIOUS DISEASES, 1997, 24 (05) :932-935
[14]   Microbiologic and pharmacodynamic principals applied to the antimicrobial susceptibility testing of ampicillin/sulbactam: Analysis of the correlations between in vitro test results and clinical response [J].
Jones, RN ;
Dudley, MN .
DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE, 1997, 28 (01) :5-18
[15]   Citywide clonal outbreak of multiresistant Acinetobacter baumannii and Pseudomonas aeruginosa in Brooklyn, NY -: The preantibiotic era has returned [J].
Landman, D ;
Quale, JM ;
Mayorga, D ;
Adedeji, A ;
Vangala, K ;
Ravishankar, J ;
Flores, C ;
Brooks, S .
ARCHIVES OF INTERNAL MEDICINE, 2002, 162 (13) :1515-1520
[16]   Multiresistant Acinetobacter infections:: a role for sulbactam combinations in overcoming an emerging worldwide problem [J].
Levin, AS .
CLINICAL MICROBIOLOGY AND INFECTION, 2002, 8 (03) :144-153
[17]   Carbapenem resistance mediated by beta-lactamases in clinical isolates of Acinetobacter baumannii in Spain [J].
López-Hernández, S ;
Alarcón, T ;
López-Brea, M .
EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES, 1998, 17 (04) :282-285
[18]   Comparative in vitro autimicrobial susceptibilities of nosocomial isolates of Acinetobacter baumannii and synergistic activities of nine antimicrobial combinations [J].
Marques, MB ;
Brookings, ES ;
Moser, SA ;
Sonke, PB ;
Waites, KB .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1997, 41 (05) :881-885
[19]  
National Committee for Clinical Laboratory Standards, 2000, M7A5 NCCLS, VM100-S10
[20]   In vitro activities of ampicillin-sulbactam and amoxicillin clavulanic acid against Acinetobacter baumannii [J].
Pandey, A ;
Kapil, A ;
Sood, S ;
Goel, V ;
Das, B ;
Seth, P .
JOURNAL OF CLINICAL MICROBIOLOGY, 1998, 36 (11) :3415-3416